Elsa Anagnostou: Pleased to see stage 1 of our ctDNA molecular response adaptive clinical trial in print.

Elsa Anagnostou, Director of Thoracic Oncology Biorepository and Associate Professor of Oncology at Johns Hopkins Medicine, made the following post on Twitter:

“Hot off the press in Nature Medicine: Pleased to see stage 1 of our ctDNA molecular response adaptive clinical trial in print, supporting the value of ctDNA as an early endpoint of immunotherapy response for patients with lung cancer.”

For details click here.
Source: Elsa Anagnostou/Twitter